Prioritizing Research in an Era of Personalized Medicine: The Potential Value of Unexplained Heterogeneity

被引:2
作者
Heath, Anna [1 ,2 ,3 ]
Pechlivanoglou, Petros [1 ,4 ]
机构
[1] Hosp Sick Children, Child Hlth Evaluat Sci, 686 Bay St Floor 11,L4 East, Toronto, ON M5G 0A4, Canada
[2] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Biostat, Toronto, ON, Canada
[3] UCL, Dept Stat Sci, London, England
[4] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
基金
加拿大自然科学与工程研究理事会; 加拿大健康研究院;
关键词
precision medicine; personalized medicine; research prioritization; study design; simulation modeling; value of heterogeneity; value of information; PROBABILISTIC SENSITIVITY-ANALYSIS; EXPECTED VALUE; ANALYSIS SAMPLE; INFORMATION; UNCERTAINTY; FRAMEWORK; MODEL;
D O I
10.1177/0272989X211072858
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Clinical care is moving from a "one size fits all" approach to a setting in which treatment decisions are based on individual treatment response, needs, preferences, and risk. Research into personalized treatment strategies aims to discover currently unknown markers that identify individuals who would benefit from treatments that are nonoptimal at the population level. Before investing in research to identify these markers, it is important to assess whether such research has the potential to generate value. Thus, this article aims to develop a framework to prioritize research into the development of new personalized treatment strategies by creating a set of measures that assess the value of personalizing care based on a set of unknown patient characteristics. Methods Generalizing ideas from the value of heterogeneity framework, we demonstrate 3 measures that assess the value of developing personalized treatment strategies. The first measure identifies the potential value of personalizing medicine within a given disease area. The next 2 measures highlight specific research priorities and subgroup structures that would lead to improved patient outcomes from the personalization of treatment decisions. Results We graphically present the 3 measures to perform sensitivity analyses around the key drivers of value, in particular, the correlation between the individual treatment benefits across the available treatment options. We illustrate these 3 measures using a previously published decision model and discuss how they can direct research in personalized medicine. Conclusion We discuss 3 measures that form the basis of a novel framework to prioritize research into novel personalized treatment strategies. Our novel framework ensures that research targets personalized treatment strategies that have high potential to improve patient outcomes and health system efficiency.
引用
收藏
页码:649 / 660
页数:12
相关论文
共 34 条
[1]   Expected value of sample information calculations in medical decision modeling [J].
Ades, AE ;
Lu, G ;
Claxton, K .
MEDICAL DECISION MAKING, 2004, 24 (02) :207-227
[2]   The path to personalised medicine in COPD [J].
Agusti, Alvar .
THORAX, 2014, 69 (09) :857-864
[3]   Value of information on preference heterogeneity and individualized care [J].
Basu, Anirban ;
Meltzer, David .
MEDICAL DECISION MAKING, 2007, 27 (02) :112-127
[4]   Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6 [J].
Briggs, Andrew H. ;
Weinstein, Milton C. ;
Fenwick, Elisabeth A. L. ;
Karnon, Jonathan ;
Sculpher, Mark J. ;
Paltiel, A. David .
VALUE IN HEALTH, 2012, 15 (06) :835-842
[5]   Bayesian value-of-infomation analysis -: An application to a policy model of Alzheimer's disease [J].
Claxton, K ;
Neumann, PJ ;
Araki, S ;
Weinstein, MC .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2001, 17 (01) :38-55
[6]   The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies [J].
Claxton, K .
JOURNAL OF HEALTH ECONOMICS, 1999, 18 (03) :341-364
[7]   Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra [J].
Claxton, K ;
Sculpher, M ;
McCabe, C ;
Briggs, A ;
Akehurst, R ;
Buxton, M ;
Brazier, J ;
O'Hagan, T .
HEALTH ECONOMICS, 2005, 14 (04) :339-347
[8]  
Claxton K, 1999, HEALTH ECON, V8, P269, DOI 10.1002/(SICI)1099-1050(199905)8:3<269::AID-HEC425>3.0.CO
[9]  
2-D
[10]   Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria [J].
Coyle, D ;
Buxton, MJ ;
O'Brien, BJ .
HEALTH ECONOMICS, 2003, 12 (05) :421-427